Citation

Che T, Teng X, Huang Q, Mu Y, Tang X, Mu X, Wei Y. Neuropsychiatr. Dis. Treat. 2018; 14: 1527-1533.

Copyright

(Copyright © 2018, Dove Press)

DOI

10.2147/NDT.S167608

PMID

unavailable

Abstract

BACKGROUND: Depressive and anxiety symptoms could seriously affect the quality of life of type 2 diabetes mellitus (T2DM) subjects. Currently, little is known about the efficacy and acceptability of agomelatine versus fluoxetine in treating these symptoms in T2DM subjects. Therefore, this study was performed to find out which one was better in treating these symptoms in T2DM subjects.

MATERIALS AND METHODS: T2DM subjects with depressive and anxiety symptoms were randomly assigned to receive either fluoxetine (30-40 mg/day) or agomelatine (25-50 mg/day). The treatment was continued for 12 weeks. The data of the Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS) were collected (at baseline and also at weeks 4, 8 and 12) to assess the depressive and anxiety symptoms, respectively. The metabolic parameters, including body mass index (BMI), fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c), were assessed at baseline and after 12 weeks of treatment. The treatment-related adverse events during the scheduled treatment period were recorded to compare the acceptability of these two drugs.

RESULTS: After 12 weeks of treatment, the average HDRS and HARS scores were significantly decreased in both groups. The average HDRS scores were not significantly different between the two groups, although the agomelatine group had a lower average HDRS score. The response and remission rates were similar between the two groups, and these two drugs had no significant effects on BMI and FPG. However, compared with the fluoxetine group, the agomelatine group had the significantly lower average HARS score (p=0.0017) and lower average HbA1c level (p<0.00001). Moreover, the incidence of adverse events was significantly lower in the agomelatine group than in the fluoxetine group (p=0.032).

CONCLUSION: Both fluoxetine and agomelatine could effectively reduce depressive and anxiety symptoms in T2DM subjects, but agomelatine might be more effective and acceptable. Future studies with more subjects are needed to support and validate our conclusion. © 2018 Che et al.

Language: en

Keywords

adult; human; Depression; female; male; insomnia; depression; anxiety; randomized controlled trial; suicide attempt; major clinical study; anorexia; vomiting; controlled study; sexual dysfunction; fluoxetine; headache; drug safety; single blind procedure; drug efficacy; diarrhea; nausea; glucose blood level; glucose; remission; non insulin dependent diabetes mellitus; Fluoxetine; diet restriction; Diabetes mellitus; dizziness; hemoglobin A1c; body mass; Article; Hamilton Anxiety Scale; agomelatine; Agomelatine; glycemic control; metabolic parameters; Hamilton Depression Rating Scale